Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleMIT Technology Review

The Download: whole-body rejuvenation drugs and five things to know about AI

View original at technologyreview.com
MIT Technology Review - Ai Research Title: The Download: whole-body rejuvenation drugs and five things to know about AI Date: 2026-06-09 12:10 Source: https://www.technologyreview.com/2026/06/09/1138604/the-download-anti-aging-drugs-ai-five-things-to-know/ <p><em>This is today’s edition of </em><a href="https://forms.t…
Opening lines of the source · MIT Technology Review · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • BYD, Baidu, Alibaba, and Unitree are aiding China's military.

    60% confidence

  • One day, people will go to the doctor and get a prescription that will make them 10 years younger.

    60% confidence

  • Oral drug mixture tests on human volunteers will provide evidence for age restoration in humans.

    60% confidence

  • AI training cannot keep up with the field's rapid advances.

    60% confidence

  • The five biggest themes in AI right now are: AI is everywhere all at once; it is getting scary; a backlash is growing; it is becoming a big deal for science; and AI itself can now do the work (he didn't need to show up to the talk).

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com